AFT Pharmaceuticals to raise $33.2 mln in IPO to fund R&D pipeline

Thu, 26 Nov 2015

Nov. 27 (BusinessDesk) - AFT Pharmaceuticals, the Auckland-based company whose products include Maxigesic pain medication and Maxiclear PE nasal decongestant, plans to raise $33.2 million to fund a research and development pipeline over the next two to three years.   The Auckland-based company set the price of 11.9 million shares to be offered at $2.80 apiece, following an institutional bookbuild, valuing AFT at $269 million, it said in a statement. The IPO includes $30.2 million of new capital to fund growth at AFT with the ability to accep...
Markets
MARKET OPEN: Kiwi holds its own as greenback falters, US equities push higher
Rebecca Howard | Thu, 06 Aug 2020

The kiwi dollar continues to hold its own as the greenback is weighed down by poor US data while the domestic share market may take cheer from a lift on Wall Street after positive earnings reports. ...

Listed Companies
Billion dollar hotel developments on backburner until better times
Brent Melville | Thu, 06 Aug 2020

Plans for at least 25 major hotel developments, valued at $2 billion, are gathering dust pending decisions on when, or if, construction will commence in the wake of border closures. The two dozen o...

Listed Companies
Pacific Edge seeks US$40m backpay from US administrator
Brent Melville | Thu, 06 Aug 2020

Pacific Edge is chasing 22,000 outstanding invoices dating back to 2015 as it seeks up to US$40 million in backpay from US medical aid administrator Novitas. The retrospective claim follows last mo...

Partner content
Don’t fear the robots. How software can help your business succeed

New Zealand businesses are on the road to recovery from the economic impact of the Covid-19 crisis but they, like corporates around the world, are having to change their operational practices.